BRAF and melanoma: BRAF-mutant melanoma cells with increased expression of EGFR are less sensitive to BRAF inhibitors [92] and elevated expression of EGFR together with NGFR characterizes pre-resistant melanoma cells, which are selected during therapy and lead to treatment failure [93].